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Fanuel Bickton (FB), an 
MMJ intern, speaks with Dr. 
Sufia Dadabhai (SD) on her 
personal and professional 
background, her position as 
the current Director of  the 
Johns Hopkins Research 
Project (JHP) in Malawi, 
the cutting-edge HIV-related studies JHP is currently 
undertaking, and specifically how the Project is positively 
impacting women's health and well-being in Malawi.
FB: What is your personal and professional background?
SD: My mum emigrated from Burma and my dad from 
India. They met in the US, and moved to California. So I 
was born and raised in California, on the West Coast of  the 
United States. My parents have always been involved in the 
community; they taught us that if  your neighbor and your 
neighbor’s neighbor are doing well, then we are all doing 
better together. I have only one sister, but many cousins, 
aunts and uncles, and we were always together growing 
up; it was a warm and lively environment to be raised in. 
I attended boarding school at Phillips Academy Andover 
in Massachusetts, and returned to the West Coast to attend 
Stanford University where I studied Human Biology and 
Religious Studies.
My mother does a lot of  international medical work - most 
recently she was here volunteering at Lions Eye Hospital. 
She’s an ophthalmologist and was probably the first one to 
introduce me to global health issues, to help me see disparities 
in quality and access to care, and the importance of  using all 
the skills we have to benefit the broader community.
I was raised by my grandmother mainly. She didn’t have 
formal education the way we know it – but she was a 
powerful woman who had the respect of  many and she 
was an excellent role model for me. I’m thankful for all the 
women in my life that set the stage for me to excel. They 
knew that circumstances for women in society are often 
more challenging than for men, but to put it simply, they 
didn’t care and pushed on.
I had a chance to work in Cape Town for one year during 
University. I applied for a clinic-based internship but it 
turned out to be very public-health focused. That was a fork-
in-the-road moment for me; I chose public health instead of  
medicine and never looked back. The organisation’s main goal 
was to reduce violence related to the ongoing HIV epidemic. 
There were a number of  myths and misunderstandings about 
HIV in the community and it was driving fear and anxiety, 
leading to violence. That was my first introduction to on-the-
ground field work, designing and delivering interventions, 
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I attended Johns Hopkins for both my Master’s and PhD – 
I’m a trained epidemiologist; my focus is infectious diseases. 
My mentor and supervisor at Johns Hopkins is Dr. Taha 
Taha, who worked in Malawi for several years. I moved to 
Blantyre in October 2015 after being appointed to the JHP 
Field Director position.
FB: How do you feel about your career as an epidemiologist 
in infectious diseases?
SD: I have always had an interest in empowering people 
with education, technologies and tools to better themselves 
and to improve their chances at a healthy life. I could have 
done that in many different ways, through teaching or the 
arts or engineering, but you have to find what you’re good 
at. My niche was research. I enjoy both the theoretical and 
applied aspects of  epidemiology. I feel fortunate to work in 
a field that I love and am motivated both internally by my 
desire to do good work and by the incredible efforts of  the 
people around me at JHP. Of  course, there are days when 
you can’t love everything about work, and that’s when you 
need exercise, or reading or social engagement to help you 
re-energize, but I do love what I do and strongly believe that 
together, researchers, advocates, health care providers and 
policy makers can really raise the bar.
FB: Tell us a brief  history of  the Johns Hopkins 
Research Project in Malawi
SD: JHP was started in 1988 – next year will mark thirty 
years in Malawi. It started very small, with a few dedicated 
and interested scientists and physicians. This was just before 
the College started, but the relationship with people who 
would soon be the faculty and founders of  COM was 
already there; the relationship with the Ministry was there. 
The initial studies looked at the basic epidemiology of  HIV: 
just understanding how HIV gets transmitted, things that 
we take for granted now, such as which body fluids transmit 
HIV, but somebody had to figure that out. The initial focus 
was on mother to child transmission; that was the interest 
and passion of  those starting the Organisation. JHP has 
expanded to include prevention and treatment research 
among adult men, non-pregnant women and adolescents. 
We’ve evolved and changed with the times based on what 
kind of  research questions are relevant to Malawi and the 
region.
FB: How has your profession as an epidemiologist 
contributed to the work you do today?
SD: Public health is an interdisciplinary field and epidemiology 
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is one area within this diverse field. To me, I feel it’s the core 
science of  public health: it’s the study of  patterns of  disease 
distribution and the causes of  those patterns. It can be as 
simple as a food-borne outbreak: Was it the cauliflower or 
broccoli? Was it the chicken or the egg salad? Where is the 
source? Now we are asking really big questions around multi-
level causes of  disease and predicting epidemic patterns that 
we haven’t even observed yet. One of  the key elements of  
epidemiology is understanding study design and bias, and 
how to design and implement a study in a way that you’ll 
actually be able to answer the question you’ve raised. Why 
is that important? Because resources are limited. So we have 
to use time, money and effort wisely. Putting effort into a 
study that’s not going to yield the information you need 
to make good public health decisions is not a good use of  
resources. That’s one reason I enjoy epidemiology – to really 
understand the best way to ask good questions and design 
good studies.
FB: How did you feel when you were told to be the 
director of  the JHP in Malawi?
SD: It was a mix of  nerves and excitement. It’s a very 
different position for me. I had never worked with a team 
this large before. We have almost 190 extremely hardworking 
and dedicated staff. So to be worthy of  being their leader 
is something I really fight for every day. Of  course, I was 
nervous about leaving a comfortable life and being far from 
friends and family. But the opportunity to have a positive 
impact on an already great organisation was extremely 
exciting.
FB: What comprises your responsibilities as the 
Director?
SD: I’d say I have four main responsibilities. One is to lead. 
That means I need to create an environment in which my 
staff  can perform their work to the best of  their abilities. 
They need to have space, supplies, training, adequate salaries 
to care for themselves, electricity, reagents, etc.; all those 
pieces need to be in place for them to succeed at the role 
that they’ve been asked to play at JHP.
I also help ensure we have enough resources, not just today 
or next month but also understanding the needs in the next 
one to three years – thinking the big picture and predicting 
changes. I work closely with our management team to best 
use the resources we all worked so hard to obtain.
I also feel really passionate about setting a positive tone at 
JHP, which is good for internal harmony and also external 
fostering collaborations. Having a positive, professional, 
pleasant work environment - that is important for the soul, 
partly because we all spend so much time at work. It starts 
with leadership to set that tone. It can be small things: keeping 
my office door open so staff  feel welcome to drop by, which 
creates an opportunity to ask how their day is going or to 
brainstorm a new idea. So much of  the work isn’t done in 
meetings or calls but in informal one-on-one interactions; 
so, being present, showing up, being available, that’s really 
important to me.
It’s also important for me to make sure we’re advancing the 
science. We are a research organisation and want to contribute 
to knowledge in a meaningful and substantive way. So, it’s my 
responsibility to ensure we are disseminating study findings 
and knowing what’s happening in the broader world of  HIV 
research and to make sure my senior staff  are also learning 
the most up-to-date information, so that we’re putting our 
energy towards the most relevant questions.
FB: What challenges do you encounter as a woman 
working in a field that is traditionally dominated by 
men? How do you overcome those challenges?
SD: I wish this didn’t have to be a question but we’d be naïve 
to think it’s not an important topic. I am honoured to be 
JHP’s first female leader. So many staff  are women and it’s 
important for junior staff  to see themselves reflected in the 
leadership of  the Organisation. The challenge is that some 
people have misinformed expectations and assumptions 
about how females in leadership should or shouldn’t behave. 
When I started this position, some were vocal to say, “Oh, 
we never thought we’d see the day with a woman as Field 
Director.” But it’s really just about who the best person is 
for the job at that time. My solution is to be unapologetic, 
keep my head up and keep doing the work. I think the hard 
work can speak for itself  and that’s what I reply on when 
facing sexism in society. You work hard, you show genuine 
interest, you excel. I have a lot of  exciting responsibilities 
here, and that doesn’t leave much time to worry about what 
others may or may not be saying. Yes, we need to be aware, 
but challenges can’t rule our days. So I guess the trick is to be 
aware, ignore the noise and get the work done.
FB: What important work is JHP currently undertaking 
in the HIV research in Malawi, and how is it contributing 
towards addressing the HIV problem in the country?
SD: There is quite a bit of  diversity in the types of  studies we 
do but broadly speaking, we are a clinical trials research team 
and we conduct HIV prevention and HIV treatment studies.
In terms of  prevention, up until now, most tools we’ve had 
are not female-operated. Negotiating condoms, abstinence, 
knowing your partner’s HIV status: these options are not 
available to all women. So we need to develop ways in which 
women can take charge of  their own health to prevent HIV. 
We are studying three different and new interventions: one 
is the monthly dapivirine vaginal ring, which slowly releases 
prophylactic levels of  an antiviral agent called dapivirine. 
Another one is an infusion study. HIV-uninfected women 
have been consented to participate in a study involving 
infusions of  monoclonal anti-HIV antibodies – which were 
developed by a research lab in the US – for the prevention 
of  HIV. It is very innovative and cutting-edge. What we 
learn from this study will move us to the next phase of  HIV 
antibody research, eventually leading to a new prevention 
agent to help women (and men) protect themselves. There’s 
also an upcoming injectable pre-exposure prophylaxis (PrEP) 
study, and the agent is called cabotegravir. We are comparing 
it to oral, daily Truvada, which is a known PrEP drug that’s 
already licensed in other countries. We know a daily pill is 
not ideal for everyone; there is a risk of  forgetting a dose or 
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losing pills or even where to store the pill if  you don’t have 
much privacy at home. So injectable options may be best 
for some women. We’re excited to be a part of  these three 
studies and our sister site, UNC-Lilongwe, is conducting 
them as well.
We also have an interesting treatment agenda. For example, 
if  someone has both malaria and HIV, what’s the appropriate 
treatment dose for clearing plasmodium from the system? 
If  a baby is infected with HIV and malnourished, will the 
baby metabolize ARTs in the same way as babies who are 
not malnourished? We are about to embark on a potentially 
game-changing study called A5349, and it’s a TB treatment 
regimen-shortening study. Right now, the standard of  
care for TB treatment involves six months of  multiple 
medications daily. If  this study is successful, the duration 
could potentially go down to four months, which is massive 
savings in terms of  adherence and total time and pill burden 
on an individual and the health care system.
We also do observational research among women living with 
HIV and their infants to track the impact of  ARV exposure 
during conception and throughout pregnancy, during delivery 
and breast-feeding. We all know that ART is a life-saving tool 
for both prevention and treatment. As more people have 
access to ART, it’s important to monitor how it impacts the 
mother’s and baby’s bodies as the baby is developing, based 
on the duration of  exposure to ART.
We are part of  a multi-site research network and some 
of  the studies we are doing here are also happening in 
Boston, Seattle, Peru, India, Thailand, Uganda, Zambia, 
etc. Teamwork with these partner sites has been critically 
important.
FB: How do you see your work impacting positively on 
reproductive health in Malawi particularly in improving 
women's health and well-being?
SD: I am proud to say that the research we have done has 
had a positive impact on both policy and practices in the 
area of  prevention of  mother-to-child transmission of  HIV. 
For example, the PEPI Study, the Pre-Exposure Prophylaxis 
for Infants Study, actually helped mold the guidelines for 
duration of  breastfeeding among HIV-infected women and 
their HIV-exposed infants. It’s rewarding when our research 
can make interventions safer, more accessible and efficacious 
than before. Similarly, we participated in in HPTN 052, 
which was a landmark study to understand how immediate 
versus deferred ART can lead to not only better health for 
HIV-infected individuals but also nearly eliminate the risk 
of  transmission to uninfected partners. That study really 
catapulted policy towards test and treat models for HIV, 
instead of  waiting until the CD4+ cell counts have dropped 
below a certain threshold. That has had a big impact on 
women’s health on a policy level.
Even on a daily basis, I feel we are impacting women’s lives. 
The women that we recruit, consent and enroll into our 
studies become part of  our team. We see some of  them for 
more hours in a day than we see our own families! Some 
of  them are in the clinics every month with a range of  
concerns and questions, and we become their standard of  
care provider even on issues that don’t relate to the study. 
Sometimes, it’s just a chat with someone who had a stressful 
day and the woman needs some counselling and motivation. 
Our participants are our partners in the work that we do, 
and they have the right to be in the study voluntarily and if  
they don’t want to be in the study, that’s also their choice. 
Respecting that choice is also empowering for women.
FB: What can you say are the factors behind the success 
of  Johns Hopkins Project?
SD: Two important factors are our reputation of  conducting 
good quality research and our history of  being the first HIV 
biomedical research institution in Malawi once news of  HIV 
first broke. We have existed through several transitions in 
the Ministry and College of  Medicine, and many changes in 
HIV in terms of  access to treatment and paradigm shifts in 
prevention.
Our Community Engagement Department has also 
contributed to the longevity of  JHP; they make sure our 
stakeholders are informed and are part of  the research we 
do; that can be City Council, the Police Department, local 
NGOs, the STI clinic nurses, COM and Queens Leadership, 
etc. They all have a stake in the research we do. None of  us 
can do the work alone and we rely heavily on mutual respect 
and sustained engagement with stakeholders to achieve our 
common goal.
When we interview new staff, there is always a question 
about teamwork. If  somebody is not good with teamwork, 
they won’t excel here at JHP. We rely a lot on communication 
between departments and have a team-based approach to 
problem-solving. Of  course, sometimes, urgent decisions 
have to be made, but teamwork is a core factor for success.
Finally, I think it’s the way we treat participants with respect 
and care, respecting the fact that they have busy, complex 
lives and they are volunteering their time to be with us. 
Sometimes they invite us to their churches to give talks or 
even to their weddings to help celebrate! These interpersonal 
relationships really matter.
So community engagement, teamwork, the way we treat 
people, commitment to quality and our longevity – these are 
all important for us.
FB: How does your Project relate with its counterparts?
SD: We are proud to be one of  several COM research 
affiliates along with Blantyre Malaria Project, Malaria Alert 
Centre, MEIRU, MLW, etc. There are always more ways to 
collaborate, to reach out and align our efforts. Time becomes 
a limiting factor but the desire and intention are there. We 
pick up the phone and call each other sometimes - How are 
you getting this done? Who’s the best person to call for this 
task? Have you used this new lab equipment before? And so 
on. So we bounce ideas off  of  one another. We have a more 
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formal partnership with some partners where we actually run 
tests for their studies, or we tap into expertise they have that 
we may not have yet. So I think the relationship is good and it 
can even be more fruitful and maximized. Time, money and 
effort are all limited resources. So, the best way to connect 
is probably to coordinate so that we don’t duplicate. There 
is plenty of  work to do and of  course, there are different 
research agendas across the organisations but what matters 
is the mutual understanding and the mutual respect for each 
other’s work and appreciation of  what an affiliate brings to 
the table.
FB: What kind of  people does JHP recruit as employees?
SD: It really depends on the position that’s available and the 
needs of  the Organisation. Where is the gap in the team 
or how can one extra person help the whole team to shine 
and do its work better? In some cases, the best person is 
someone very seasoned in research. We also work with a 
number of  people who are quite ‘green’ or new to research, 
but we see their passion for research and that research is part 
of  their long-term career trajectory. For a number of  our 
staff, they came to the interview and didn’t know anything 
about clinical trials but they expressed passion to learn and 
be excellent, and came at the right place and the right time. 
So a number of  pieces have to come together. We welcome 
people from a wide range of  disciplines and skill levels.
FB: What outstanding life experiences or achievements 
are you proudest of ?
SD: That’s a big question! Probably this position that I have 
right now. Serving the team here has been a huge source of  
professional and personal joy for me. Again, I think the work 
that we do is good for the community, good for Malawi, and 
good for global health. I haven’t gotten here alone, certainly; 
I mentioned a number of  role models – my parents, 
grandparents and sister – who have always applauded my 
successes but also propelled me to do better each day I walk 
through these doors. This work is not easy; it takes a lot of  
time to do it right and can be exhausting at times. But you do 
it because you love it.
FB: Lastly, what is your vision for JHP?
SD: I value every life equally and that’s what keeps me 
motivated. That’s really important in a world full of  disparities 
and differences in access to resources, people born into 
different geographies and different family dynamics, different 
access to education, etc. I think it’s critically important to 
value every life equally and that relates to the vision I have 
for JHP. I believe that through high quality, collaborative 
research and training opportunities, we can create a world 
in which every person has the opportunity to live a healthy, 
long life. We can’t do it alone but I think that’s our piece of  
the puzzle, that’s what epidemiology and JHP can bring to 
the table. Long after I’ve left JHP, I will ask myself, “Did 
we have some real impact?” I hope the answer is yes, and 
it will be because through research, we made a change in 
population health, in someone’s life and opportunities that 
person has to shine.
© 2017 The College of  Medicine and the Medical Association of  Malawi. This work is licensed under the Creative Commons Attribution 4.0 International License.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
